ECONOMIC MODEL TO EXAMINE THE COST BENEFIT ASSOCIATED WITH RESOLUTION OR IMPROVEMENT OF CARCINOID SYNDROME SYMPTOMS FOLLOWING TREATMENT WITH ABOVE-STANDARD DOSE OF OCTREOTIDE-LAR IN PATIENTS WITH NEUROENDOCRINE TUMORS BASED ON DATA FROM A R ...
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1047
https://www.valueinhealthjournal.com/article/S1098-3015(16)01115-3/fulltext
Title :
ECONOMIC MODEL TO EXAMINE THE COST BENEFIT ASSOCIATED WITH RESOLUTION OR IMPROVEMENT OF CARCINOID SYNDROME SYMPTOMS FOLLOWING TREATMENT WITH ABOVE-STANDARD DOSE OF OCTREOTIDE-LAR IN PATIENTS WITH NEUROENDOCRINE TUMORS BASED ON DATA FROM A R ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01115-3&doi=10.1016/j.jval.2016.03.1047
First page :
A245
Section Title :
Systemic Disorders/Conditions - Cost Studies
Open access? :
No
Section Order :
896